William John Sibold Sells 6,362 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Posted by George Bondi on Sep 11th, 2026

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) CEO William Sibold sold 6,362 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total value of $3,407,423.58. Following the transaction, the chief executive officer owned 202,967 shares of the company’s stock, valued at $108,707,095.53. The trade was a 3.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

William John Sibold also recently made the following trade(s):

On Friday, September 11th, William Sibold sold 5,221 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $542.39, for a total transaction of $2,831,818.19.

Madrigal Pharmaceuticals Stock Up 0.3%

MDGL stock traded up $1.37 during trading on Friday, hitting $534.49. 187,642 shares of the stock traded hands, compared to its average volume of 339,731. Madrigal Pharmaceuticals, Inc. has a 1 year low of $393.61 and a 1 year high of $615.00. The firm’s 50 day moving average is $530.87 and its two-hundred day moving average is $507.44. The stock has a market cap of $12.35 billion, a price-to-earnings ratio of -41.47 and a beta of -0.98. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.20 and a quick ratio of 2.94.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.68) by $0.69. The business had revenue of $364.25 million during the quarter, compared to analysts’ expectations of $352.13 million. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. The business’s revenue for the quarter was up 71.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.90) earnings per share. On average, sell-side analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -7.03 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. HC Wainwright reiterated a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 31st. Citigroup reaffirmed an “outperform” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, June 24th. Bank of America reduced their price objective on Madrigal Pharmaceuticals from $550.00 to $542.00 and set a “neutral” rating for the company in a report on Thursday, June 11th. Finally, Wolfe Research raised Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 target price for the company in a research report on Tuesday, August 4th. Fifteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $699.64.

Read Our Latest Analysis on MDGL

Institutional Trading of Madrigal Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Persistent Asset Partners Ltd purchased a new position in Madrigal Pharmaceuticals in the second quarter worth about $29,000. Global Retirement Partners LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the 2nd quarter valued at about $34,000. Kemnay Advisory Services Inc. bought a new position in shares of Madrigal Pharmaceuticals in the 4th quarter worth approximately $39,000. Quarry LP bought a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter worth approximately $39,000. Finally, Accent Capital Management LLC lifted its stake in shares of Madrigal Pharmaceuticals by 64.9% in the 4th quarter. Accent Capital Management LLC now owns 94 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 37 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.

About Madrigal Pharmaceuticals

(Get Free Report)

Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL) is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic diseases, particularly nonalcoholic steatohepatitis, now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH).

The company’s lead product is Rezdiffra (resmetirom), an oral, thyroid hormone receptor beta agonist designed to target underlying liver disease. In 2024, the U.S. Food and Drug Administration approved Rezdiffra for use with diet and exercise to treat adults with noncirrhotic MASH and moderate to advanced liver fibrosis.